Navigation Links
Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
Date:2/20/2008

would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter- related infections.

Forward-Looking Statements

Cadence cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. These forward-looking statements include statements regarding the advancement of the company's clinical development programs for its product candidates, the timeframes in which the company expects to file submissions with regulatory authorities seeking marketing authorization for its product candidates, and the adequacy of the company's funding to advance its product candidates through to NDA submissions. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Cadence's business, including, without limitation: Cadence's dependence on the success of its only two product candidates; delays in completing the company's clinical trials or achieving its product development goals, or significant issues regarding the results, design or execution of its clinical trials; the potential need to expand Cadence's ongoing clinical trials or to conduct additional clinical trials; the market potential for the company's product candidates, and its ability to compete with new or existing products; unanticipated adverse side effects or inadequate therapeutic efficacy of its product candidates; delays or quality issues
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
2. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIO Investor Forum
6. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference
7. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
10. Vion Pharmaceuticals to Implement a One-for-Ten Reverse Stock Split
11. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...re/ -- The world,s first concept demonstration t...ugh alternative to replace a petrochemically produ...ber with renewable biomass, made their debut in Co...display at a lounge in the common departure area a...December 21, while the other tire will make appear...
(Date:12/2/2009)...swire-FirstCall/ - Oncolytics Biotech Inc. ("Oncol...announced today that in connection with its previo...e exercised in full their over-allotment option an... is comprised of one common share and 0.4 of a com...e of US$3.00 per unit. Each whole common share pur...
(Date:12/2/2009)...s, December 2 Pepscan Holding NV,...ng on protein mimicking,technology for the generat...,has appointed Wim E.M. Mol, Ph.D. as new Chief Ex...sible for all of Pepscans corporate functions and,...the company. He brings to,Pepscan more than 20 yea...
(Date:12/2/2009)... December 2 Gamida Cell announced ...al (animal study) safety and,efficacy of a gene th...,Cornell Medical College and Gamida Cell. The prod...such as Cooley,s Anemia. , Gamida Cell is... vivo,populations of stem/progenitor cells. The c...
Breaking Biology Technology:The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 2The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4Dutch Biotech Company Pepscan Appoints New CEO 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3
...today,announced the appointment of industry vetera... further bolstering its position as a leader in th...Mr. Bailye, 54, recently retired from his position... Dendrite was acquired by French information,provi...te, a pharmaceutical,sales force automation system...
...HERAL VASCULAR DEVICE MARKET INSIGHTS WEBINAR ... Thursday, June 5, 2008, 11 am US Eastern Ti...s), PRESENTER: Stephanie LaBelle, Analyst from ...e the link below to register or call Shiu-Yik Au a...Research Group presents a complimentary Webinar ou...
...ire-FirstCall/ - Quest PharmaTech Inc. (TSX-V:,QPT...t its 12-patient,Phase I clinical study entitled "...todynamic Therapy of Actinic Keratosis" has met bo...re delighted to have received, for the first time,...in a dermatological application,",said Madi R. Mad...
Other Biology Technology:IntegriChain Appoints John Bailye to Its Board of Directors 2Peripheral Vascular Device Market Insights Webinar 2Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis 2Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis 3
(Date:12/3/2009)... investment in energy efficient technologies resea...h Council (EPSRC) Chief Executive Dave Delpy belie...ng research has already brought us fuel cells, mar...stment is needed to develop the capabilities of di...ssion targets by 2020 and limit the impact of clim...
(Date:12/2/2009)...ino men have a more difficult time quitting smokin...ture, but acculturation has no affect on Latinas o... are published in Cancer Epidemiology, Biomarkers...ion for Cancer Research. The December issue has a ...ts smoking cessation differently for Latino men an...
(Date:12/2/2009)...cents exposed to cigarette smoking scenes in movie... and this may be part of the acculturation process...new study findings. , "Our study supports an R-r...hts the global implementation of the World Health ...ol, which includes guidelines for countries to res...
Breaking Biology News(10 mins):Research is vital to a cleaner, greener, low carbon future 2Acculturation affects smoking cessation success among Latinos 2Watching movies featuring characters who smoke negatively influences Mexican-American teens 2Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hema 6741 1Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hema 6741 2Blood Clot Threat After Surgery Worse Than Thought 62571 1Blood Clot Threat After Surgery Worse Than Thought 62571 2Blood Clot Threat After Surgery Worse Than Thought 62571 3Blood Sugar Intolerance May Predict Postpartum Ills 62567 1Blood Sugar Intolerance May Predict Postpartum Ills 62567 2
...TON, DC -- Sweetpotatoes, often misunderstood and ...saving food crop in developing countries. , Accor...tato.org ), more than 95 percent of the global swe...ere it is the fifth most important food crop. Desp...e potato. Potatoes are tubers (referring to their ...
...ts have identified a new way to breed brassicas, w...esistant to a damaging virus. Their discovery has ... be durable, broad-spectrum and unlikely to be ove...(TuMV) is an economically devastating virus that i...cially brassicas. In research published recently i...
...ama Barkai will receive the Helen and Martin Kimme...v. 5 at the Weizmann Institute. The award is accom...er five years. , Taking a chance on an experiment.... Living cells are, from this angle, great subject... have all sorts of interesting consequences for ma...
Other Biology News:Sweet potato shines as new promise for small enterprise and hunger relief in developing countries 2Sweet potato shines as new promise for small enterprise and hunger relief in developing countries 3Genes identified to protect brassicas from damaging disease 2Weizmann Institute scientists discover: A 'risk distribution law' for evolution 2
Biolase Core Kit from Bioline
...amplification of GC-rich nucleic acids ,The GC-... a proofreading polymerase, powers through templat...h other polymerases and other blends of polymerase...unique GC-RICH Resolution Solution combine to deli...
...nogen: synthetic peptide corresponding to the thir..., conjugated to KLH. The immunizing peptide has 79...form: Solution in phosphate buffered saline, pH 7....d: IHC (p). Titertest values: immunohistochemistr...
CnC (Cn402-05) from European Collection of Cell Cultures (ECACC)
Biology Products: